本文關(guān)鍵詞：中國(guó)食管癌高發(fā)區(qū)食管癌前病變分布特征及其進(jìn)展規(guī)律研究　出處：《北京協(xié)和醫(yī)學(xué)院》2016年碩士論文　論文類型：學(xué)位論文

  更多相關(guān)文章： 食管癌 內(nèi)鏡篩查 依從性 檢出率參考值范圍 隨診間隔

【摘要】：研究目的基于河南林州、河北磁縣和山東肥城三個(gè)食管癌早診早治示范基地內(nèi)鏡篩查項(xiàng)目,描述我國(guó)食管癌高發(fā)區(qū)食管癌及其癌前病變分布、進(jìn)展、發(fā)病/死亡規(guī)律,為制定不同級(jí)別癌前病變檢出率參考值范圍及隨診間隔,優(yōu)化現(xiàn)行食管癌早診早治項(xiàng)目技術(shù)方案提供科學(xué)依據(jù)。材料與方法本研究為基于自然人群的多中心橫斷面研究。依托我國(guó)食管癌高發(fā)區(qū)河南林州、河北磁縣、山東肥城2005年-2009年完成篩查的自然人群隊(duì)列,選擇40-69歲使用內(nèi)鏡下碘染色及指示性活檢技術(shù)進(jìn)行篩查并有明確病理學(xué)診斷的篩查者為研究對(duì)象,回顧性整理其病理診斷結(jié)果。計(jì)算內(nèi)鏡篩查依從性,χ2檢驗(yàn)比較食管癌及其癌前病變性別、地區(qū)、年齡分布差異,采用95%CI值分析食管癌及其癌前病變檢出率范圍。以2005-2009年進(jìn)行內(nèi)鏡篩查、有明確病理診斷且未經(jīng)過(guò)治療的食管癌及其癌前病變患者為研究對(duì)象,進(jìn)行二次內(nèi)鏡隨訪。計(jì)算兩次內(nèi)鏡時(shí)間間隔,并比較前后兩次內(nèi)鏡病理診斷結(jié)果,計(jì)算每年各級(jí)別癌前病變累積進(jìn)展例數(shù)及累積進(jìn)展概率,并進(jìn)行性別、年齡別累積進(jìn)展概率的比較。收集整理篩查覆蓋人群發(fā)病、死亡等終點(diǎn)結(jié)局資料,采用趨勢(shì)x2檢驗(yàn)計(jì)算每一年不同級(jí)別病理診斷者累計(jì)發(fā)病、死亡率；x2檢驗(yàn)比較各級(jí)別病理診斷研究對(duì)象中,不同性別、年齡別間發(fā)病率、死亡率的差別;對(duì)輕度不典型增生者3年累計(jì)發(fā)病率與其他每年累計(jì)發(fā)病率比較；對(duì)中度不典型增生者1年累計(jì)發(fā)病率與其他每年累計(jì)發(fā)病率比較。研究結(jié)果1.本研究覆蓋人群99060人,其中40-69歲人群46568人,首次參與內(nèi)鏡篩查人數(shù)為21955人,內(nèi)鏡篩查順應(yīng)性為47.15%。其中女性(50.91%,11739/23058)依從性高于男性(43.45%,10216/23510)(x2=47.15,P0.001)。排除活檢組織過(guò)小不足以診斷191人,共計(jì)21764人納入本研究。食管病變檢出率為24.65%(5365/21764)。其中基底細(xì)胞增生1729例(7.94%,95% CI：7.59%-8.30%),低級(jí)別上皮內(nèi)瘤變3163例(14.53%,95%CI：14.06%-15.00%),高級(jí)別上皮內(nèi)瘤變335例(1.54%,95%CI：1.38%-1.70%),食管癌138例(0.63%,95%CI：0.53%-0.74%)。檢出率從高到低依次為：低級(jí)別上皮內(nèi)瘤變基底細(xì)胞增生高級(jí)別上皮內(nèi)瘤變食管癌。在食管癌及各級(jí)癌前病變中,男性檢出率均顯著高于女性。基底細(xì)胞增生男、女檢出率分別為9.05%和6.98%(x2=19.438,P0.001)；低級(jí)別.上皮內(nèi)瘤變男、女檢出率分別為15.85%和13.38%(x2=26.661,P0.001)；高級(jí)別_上皮內(nèi)瘤變男、女檢出率分別為1.74%和1.37%(x2=4.865,P=0.027)；食管癌男、女檢出率分別為0.85%和0.45%(x2=13.829,P0.001)。基底細(xì)胞增生、低級(jí)別上皮內(nèi)瘤變、高級(jí)別上皮內(nèi)癌變和食管癌檢出率均有隨年齡增加而增加的趨勢(shì),趨勢(shì)x2檢驗(yàn)均有統(tǒng)計(jì)學(xué)意義。40～44歲調(diào)查對(duì)象各級(jí)別癌前病變檢出率最低,分別為7.61%(425/5585)、6.70%(374/5585)、0.34%(19/5585)和0.18%(10/5585)；65-69歲調(diào)查對(duì)象分別為8.14%(84/1093)、21.87%(239/1093)、3.84%(42/1093)和1.92%(21/1093)。并且在每一個(gè)年齡組中,檢出率由高到低均為低級(jí)別上皮內(nèi)瘤變基底細(xì)胞增生高級(jí)別上皮內(nèi)瘤變食管癌。林州、磁縣、肥城三地各級(jí)食管癌前病變檢出率均不同,其差別有統(tǒng)計(jì)學(xué)意義；其中,基底細(xì)胞增生檢出率磁縣最高,為18.57%(1136/6116).低級(jí)別上皮內(nèi)瘤變和高級(jí)別上皮內(nèi)瘤變檢出率均為林州最高,分別為17.40%(1787/10269)和1.80%(185/10269)。三地食管癌檢出率差別無(wú)統(tǒng)計(jì)學(xué)意義(Z2=0.613,P=0.736)。2.2005-2009年進(jìn)行內(nèi)鏡篩查的人群共21955人,在9年里共計(jì)隨訪2389人,內(nèi)鏡篩查依從性為10.88%,其中男性內(nèi)鏡篩查依從性為11.26%,女性內(nèi)鏡篩查依從性為10.55%,二者差別無(wú)統(tǒng)計(jì)學(xué)意義(x2=0.096,P=0.099)。三個(gè)食管癌早診早治示范基地二次內(nèi)鏡篩查依從性均較低,其中,林州二次內(nèi)鏡篩查依從性最高,為15.81%,磁縣二次內(nèi)鏡篩查依從性最低,僅為4.5%。在隨訪的前七年,中度不典型增生累積進(jìn)展率始終高于輕度不典型增生；隨訪第七年開(kāi)始,二者累積進(jìn)展率交叉。對(duì)于輕度不典型增生,2-4年累積進(jìn)展率由0.18%進(jìn)展為1.07%,累積進(jìn)展率較低,且變化幅度不大,到第5年及以后每年進(jìn)展率加快,均增長(zhǎng)1個(gè)百分點(diǎn)以上；對(duì)于中度不典型增生,2-4年累積進(jìn)展率較高,為3.33%-3.59%,但變化幅度不大,4-5年由3.59%進(jìn)展為4.62%；對(duì)于低級(jí)別上皮內(nèi)瘤變,也有類似上述輕度不典型增生和中度不典型增生的規(guī)律。男性中度不典型增生隨訪2-9年累積進(jìn)展率(5.29%-10.58%)始終大于輕度不典型增生(0.18%-7.18%)；女性中度不典型2-4年累積進(jìn)展率高于輕度不典型增生,5年之后低于輕度不典型增生。各年齡組中,在隨訪最初,中度不典型增生累積進(jìn)展率均顯著高于輕度不典型增生,隨后該差異逐漸減小,40-49歲組在隨訪第7年、50-59歲組在隨訪第8年,輕度不典型增生累積進(jìn)展率開(kāi)始高于中度不典型增生。3.在我國(guó)食管癌高發(fā)區(qū),內(nèi)鏡篩查并隨訪10年后,各級(jí)別病理診斷研究對(duì)象食管癌累計(jì)發(fā)病率/死亡率均呈上升趨勢(shì),趨勢(shì)卡方檢驗(yàn)均有統(tǒng)計(jì)學(xué)意義。在每一年中,發(fā)病率/死亡率大小均為中度不典型增生輕度不典型增生基底細(xì)胞增生正常。男性食管癌累計(jì)發(fā)病率/死亡率高于女性；食管癌累計(jì)發(fā)病率／死亡率隨年齡增加而增加。輕度不典型增生3年累計(jì)發(fā)病率與1-6年累計(jì)發(fā)病率比較,無(wú)顯著差異,(P0.05),直至第7年,二者比較差異有統(tǒng)計(jì)學(xué)意義(x2=5.286,P=0.021)；中度不典型增生1年累計(jì)發(fā)病率與2-4年累計(jì)發(fā)病率比較,無(wú)顯著差異(P0.05),直至第5年,二者比較差異有統(tǒng)計(jì)學(xué)意義x2=11.465,P=0.001。結(jié)論我國(guó)食管癌高發(fā)區(qū)自然人群中存在大量無(wú)癥狀癌前病變及癌癥患者,癌前病變檢出率與年齡、性別密切相關(guān),高發(fā)區(qū)早診早治應(yīng)進(jìn)一步加強(qiáng)健康教育和組織發(fā)動(dòng),進(jìn)一步提高癌前病變檢出率,尤其應(yīng)提高男性以及高年齡篩查對(duì)象參加篩查依從性避免癌前病變漏診,從而提高篩查效果。中度不典型增生累積進(jìn)展率及食管癌發(fā)生、死亡風(fēng)險(xiǎn)均高于輕度不典型增生。中度不典型增生累積進(jìn)展率及食管癌發(fā)病、死亡率4年內(nèi)變化不大,輕度不典型增生累積進(jìn)展率及食管癌發(fā)病、死亡率5年內(nèi)變化不大,建議對(duì)中度不典型增生3-4年進(jìn)行一次隨訪,輕度不典型增生患者每5-6年進(jìn)行一次隨訪。
[Abstract]:Based on the purpose of early diagnosis in Henan Linzhou, Hebei Cixian and Shandong Feicheng three esophageal cancer early treatment demonstration base of endoscopic screening project, described China's high incidence area of esophageal cancer esophageal cancer and its precancerous lesion distribution, pathogenesis, progress / death rules for different levels of precancerous lesions and the detection rate of the reference value range and follow-up interval optimization of early diagnosis of esophageal cancer, the early treatment project technical solutions and provide scientific basis for. Materials and methods this study was a multicenter cross-sectional study based on natural populations. Relying on China's high incidence area for esophageal cancer in Linzhou, Henan, Hebei Cixian, Shandong Feicheng in 2005 -2009 years to complete the screening queue natural population, aged 40-69 years old were chosen using iodine staining under endoscopy and biopsy technique for screening and definite pathological diagnosis screening as the research object, retrospectively collected the pathological diagnosis results. The compliance of endoscopic screening was calculated. Chi square test was used to compare the difference of sex, region and age distribution between esophageal cancer and precancerous lesion. The 95%CI value was used to analyze the detection rate of esophageal cancer and its precancerous lesions. The 2 groups were compared. The endoscopic screening, pathological diagnosis and treatment of esophageal cancer and precancerous lesions in 2005-2009 years were carried out in two patients. The time interval between the two endoscopic intervals was calculated, and the endoscopic diagnostic results were compared before and after two times. The cumulative progression rate and cumulative progress probability of precancerous lesions at various levels were calculated annually, and the cumulative progress probability of gender and age was compared. Collect the death incidence and population screening cover end point outcome data using the trend, calculated by x2 test every year, different levels of pathologic diagnosis, the cumulative incidence of mortality; x2 test comparing the level of pathological diagnosis study in different gender and age between the incidence rate and death rate difference; for mild dysplasia in 3 year cumulative incidence compared with other year cumulative incidence of moderate dysplasia; 1 year cumulative incidence compared with other year cumulative incidence. Results of the study, 1. subjects covered 99060 people, of which 46568 were 40-69 years old, and 21955 were screened for the first time in endoscopic screening and 47.15% for endoscopic screening. The compliance of women (50.91%, 11739/23058) was higher than that of men (43.45%, 10216/23510) (x2=47.15, P0.001). The removal of biopsy tissue was not enough to diagnose 191 people, and a total of 21764 people were included in this study. The detection rate of esophageal lesions was 24.65% (5365/21764). Basal cell hyperplasia was seen in 1729 cases (7.94%, 95% CI:7.59%-8.30%), low grade intraepithelial neoplasia in 3163 cases (14.53%, 95%CI:14.06%-15.00%), high-grade intraepithelial neoplasia in 335 cases (1.54%, 95%CI:1.38%-1.70%), and esophageal cancer in 138 cases (0.63%, 95%CI:0.53%-0.74%). The rate of detection is from high to low in the following order: low grade intraepithelial neoplasia and high grade intraepithelial neoplasia of esophagus. In the esophageal cancer and the precancerous lesions at all levels, the male detection rate was significantly higher than that of the female. Basal cell hyperplasia of male and female detection rates were 9.05% and 6.98% (x2=19.438, P0.001); low level. Male and female detection rates were 15.85% and 13.38% intraepithelial neoplasia (x2=26.661, P0.001); high grade intraepithelial neoplasia _ male and female detection rates were 1.74% and 1.37% (x2=4.865, P=0.027) esophageal cancer; male and female detection rates were 0.85% and 0.45% (x2=13.829, P0.001). The detection rates of basal cell proliferation, low-grade intraepithelial neoplasia, high-grade intraepithelial neoplasia and esophageal cancer all increased with age. The trend of x2 test was statistically significant. At the age of 40~44, the detection rate of precancerous lesions at all levels was the lowest, which were 7.61% (425/5585), 6.70% (374/5585), 0.34% (19/5585) and 0.18% (10/5585) respectively, and 65-69 years old subjects were 8.14% (84/1093), 21.87% (239/1093), 3.84% (42/1093) and 1.92% (21/1093), respectively. And in each age group, the detection rate was from high to low to low grade intraepithelial neoplasia and high grade of intraepithelial neoplasia. Linzhou, Cixian, Feicheng and three levels of esophageal precancerous lesion detection rate were different, the difference was statistically significant; the basal cell hyperplasia detection rate of Cixian is the highest, was 18.57% (1136/6116). Low grade intraepithelial neoplasia and high grade intraepithelial neoplasia detection rate was highest in Linzhou, were 17.40% (1787/10269) and 1.80% (185/10269). There was no significant difference in the detection rate of three esophageal carcinoma (Z2=0.613, P=0.736). A total of 21955 people screened for endoscopy in 2.2005-2009 were enrolled in the past 9 years. 2389 patients were followed up for 9 years. The adherence of endoscopic screening was 10.88%, of which 11.26% of male endoscopy screening and 10.55% of female endoscopic screening were not statistically significant (x2=0.096, P=0.099). Three esophageal cancer early diagnosis and treatment demonstration base two endoscopic screening compliance is relatively low, of which Linzhou two endoscopic screening compliance is the highest, 15.81%, Cixian two endoscopic screening compliance is the lowest, only 4.5%. In the first seven years of follow-up, the cumulative progression rate of moderate atypical hyperplasia was always higher than that of mild atypical hyperplasia; after seventh years of follow-up, the cumulative rate of progress of the two was cross. For mild dysplasia, 2-4 year cumulative progress rate from 0.18% in 1.07%, the cumulative progress rate is low, and the change is not obvious, to the fifth year and later progress rate, average growth of more than 1 percentage points; for moderate dysplasia, 2-4 year cumulative progress rate is higher, but the change rate is 3.33%-3.59%, little 4-5 by the 3.59% progress is 4.62%; for low grade intraepithelial neoplasia, also have similar mild dysplasia and moderate dysplasia of the law. Male moderate atypical hyperplasia followed up for 2-9 years. The cumulative progression rate (5.29%-10.58%) was always higher than that of mild atypical hyperplasia (0.18%-7.18%). The cumulative progression rate of female moderate atypical 2-4 years was higher than that of mild atypical hyperplasia, and 5 years later, it was lower than mild atypical hyperplasia. In all age groups, the cumulative progression rate of moderate atypical hyperplasia was significant at the beginning of the follow-up.
【學(xué)位授予單位】：北京協(xié)和醫(yī)學(xué)院
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類號(hào)】：R735.1

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 陳碧魂,劉健,周扣珍;子宮頸鱗狀上皮癌與不典型增生的電鏡觀察[J];第一軍醫(yī)大學(xué)學(xué)報(bào);1990年03期

2 李強(qiáng);孫媛媛;曲善穎;劉威;;不典型增生的胃黏膜形態(tài)變化臨床分析[J];中國(guó)傷殘醫(yī)學(xué);2014年03期

3 賈嘉興;;人體組織的不典型增生會(huì)發(fā)生癌變嗎[J];求醫(yī)問(wèn)藥;2009年04期

4 劉復(fù)生;不典型增生(atypical hyperplasia)[J];中國(guó)骨腫瘤骨病;2002年03期

5 葉學(xué)正;胃的不典型增生的意義及病理診斷標(biāo)準(zhǔn)[J];國(guó)外醫(yī)學(xué)(腫瘤學(xué)分冊(cè));1985年04期

6 寧渝,劉鋼;胃潰瘍伴不典型增生2例報(bào)告[J];重慶醫(yī)藥;1990年01期

7 郭振華;金建軍;;胃黏膜不典型增生患者血清胃泌素及生長(zhǎng)激素的檢測(cè)及意義[J];河南科技大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2012年02期

8 張黎明;劉華;劉莉莉;劉希雙;;胃黏膜不典型增生患者的內(nèi)鏡隨訪和治療價(jià)值分析[J];中國(guó)全科醫(yī)學(xué);2013年32期

9 林一帆,陳希陶,胡家露,丁華野,朱明華,張學(xué)庸;胃粘膜不典型增生核仁組成區(qū)嗜銀蛋白的圖像分析研究[J];中國(guó)腫瘤臨床;1994年02期

10 陳素萍,李敏;54例胃粘膜不典型增生的病理分析[J];甘肅科技情報(bào);1995年05期

相關(guān)會(huì)議論文 前6條

1 相加慶;李鶴成;張亞偉;胡鴻;馬龍飛;繆隴升;;食管上皮高度不典型增生的處理[A];全國(guó)食管癌診斷與治療新技術(shù)研討會(huì)論文集[C];2006年

2 吳曉英;肖志強(qiáng);陳主初;李萃;汪春年;李建玲;馮雪萍;張蓬輝;;人支氣管上皮不典型增生與浸潤(rùn)癌組織的比較蛋白質(zhì)組學(xué)研究[A];中國(guó)蛋白質(zhì)組學(xué)第二屆學(xué)術(shù)大會(huì)論文摘要論文集[C];2004年

3 唐郡;彭貴勇;孫永剛;陳磊;李向紅;;內(nèi)鏡下氬等離子凝固治療食管黏膜不典型增生的臨床研究[A];中華醫(yī)學(xué)會(huì)第七次全國(guó)消化病學(xué)術(shù)會(huì)議論文匯編（下冊(cè)）[C];2007年

4 鄭世營(yíng);葛錦峰;趙軍;蔣東;李凱;成飛;;食管鱗癌及不典型增生組織Fas／FasL的表達(dá)[A];第八屆華東六省一市胸心血管外科學(xué)術(shù)會(huì)議論文匯編[C];2005年

5 鄭世營(yíng);葛錦峰;趙軍;蔣東;李凱;成飛;;食管鱗癌及不典型增生組織Fas／FasL的表達(dá)[A];中華醫(yī)學(xué)會(huì)第六次全國(guó)胸心血管外科學(xué)術(shù)會(huì)議論文集（胸外科分冊(cè)）[C];2006年

6 周揚(yáng);高靜;田亞平;;胃癌與不典型增生生物化學(xué)鑒別診斷方法探索[A];第七屆全國(guó)醫(yī)學(xué)生物化學(xué)與分子生物學(xué)和第四屆全國(guó)臨床應(yīng)用生物化學(xué)與分子生物學(xué)聯(lián)合學(xué)術(shù)研討會(huì)暨醫(yī)學(xué)生化分會(huì)會(huì)員代表大會(huì)論文集[C];2011年

相關(guān)重要報(bào)紙文章 前1條

1 中國(guó)消費(fèi)者報(bào) 王洪武;用激光照射不典型增生的食管黏膜上皮可防止食管癌變[N];中國(guó)消費(fèi)者報(bào);2005年

相關(guān)博士學(xué)位論文 前1條

1 秦韻;早期子宮內(nèi)膜癌和高度不典型增生保留生育功能治療的預(yù)后結(jié)局分析[D];北京協(xié)和醫(yī)學(xué)院;2016年

相關(guān)碩士學(xué)位論文 前3條

1 王孟;中國(guó)食管癌高發(fā)區(qū)食管癌前病變分布特征及其進(jìn)展規(guī)律研究[D];北京協(xié)和醫(yī)學(xué)院;2016年

2 黃謙;肺泡上皮不典型增生EGFR表達(dá)和突變的意義研究[D];中南大學(xué);2013年

3 覃菊芳;子宮內(nèi)膜不典型增生手術(shù)前后診斷符合率臨床分析[D];廣西醫(yī)科大學(xué);2009年

，

本文編號(hào)：1341114